Drug intelligence / Profile preview

Jitongning (Tasly Pharmaceutical Group Co., Ltd.)

Development stage: Unknown
Lead developer: Tasly Pharmaceutical
Administration: Oral

Overview

Jitongning (Jitongning Pian) is a Traditional Chinese Medicine (TCM) product developed by Tianjin Tasly Pharmaceutical for the treatment of active axial spondyloarthritis (ax-SpA). It is formulated as an oral tablet and is intended to improve symptoms and functional outcomes in patients with spondyloarthritis. The drug is currently being evaluated in Phase 2 clinical trials in China to determine its efficacy, specifically measuring the proportion of subjects achieving an ASAS20 response. As a botanical-based therapy, it is thought to provide anti-inflammatory and analgesic benefits through the synergistic effects of its herbal components.

Brand names: Jitongning Pian
Other names: Jitongning tablets

Beyond the preview

Go deeper on Jitongning (Tasly Pharmaceutical Group Co., Ltd.).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jitongning (Tasly Pharmaceutical Group Co., Ltd.).

Explore the full profile